drugset

drugset / Trial / NCT01554618

Safety and Efficacy Study of Exenatide Once Weekly in Adolescents With Type 2 Diabetes

NCT01554618 ↗

Phase 3 Completed 84 enrolled AstraZeneca

RandomizedParallel-groupQuadruple-blindTreatment

Summary

The study examines the Safety and efficacy study of exenatide once weekly in children and adolescents with type 2 diabetes

Timeline

Start: 2011-12-02
Primary completion: 2020-05-06
Completion: 2021-05-05

Publications

Tamborlane WV, Bishai R, Geller D, Shehadeh N, Al-Abdulrazzaq D, Vazquez EM, Karoly E, Troja T, Doehring O, Carter D, Monyak J, Sjostrom CD. Once-Weekly Exenatide in Youth With Type 2 Diabetes. Diabetes Care. 2022 Aug 1;45(8):1833-1840. doi: 10.2337/dc21-2275.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Exenatide	Peptide	2 mg	—

Indications

No indication recorded.